Views 300
Citations 0
News From the Food and Drug Administration
May 17, 2016

New Morcellation System Does Not Eliminate Cancer Risk

Author Affiliations

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2016;315(19):2057. doi:10.1001/jama.2016.5579

The FDA has approved the first tissue containment system for use with certain laparoscopic power morcellators to isolate uterine tissue that isn’t suspected to be cancerous.

Surgeons use power morcellation during minimally invasive hysterectomy or myomectomy to cut tissue into tiny portions, facilitating removal. The practice has been scrutinized in recent years because it may spread fragments of undetected uterine sarcomas throughout the abdominal cavity (Hampton T. JAMA. 2014;311[9]:891-893). About 1 in 350 women who undergo hysterectomy or myomectomy for fibroids has unsuspected uterine sarcoma, the FDA noted.

First Page Preview View Large
First page PDF preview
First page PDF preview